Cefiderocol received FDA approval in 2019. The antibiotic was approved on December 20, 2019, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative bacteria [1].
What kind of infections does Cefiderocol treat?
Cefiderocol is indicated for patients 18 years of age and older with cUTI, including kidney infections (pyelonephritis), where treatment options are limited due to resistance to other antibacterial drugs [1]. It is particularly useful against challenging Gram-negative pathogens like Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and Enterobacterales that exhibit carbapenem resistance [2].
How does Cefiderocol work?
Cefiderocol is a siderophore cephalosporin. It enters bacterial cells by binding to the ferric iron transport system, a mechanism that is often preserved even in bacteria resistant to other beta-lactam antibiotics. Once inside the cell, it inhibits bacterial cell wall synthesis, leading to bacterial death [2].
When does Cefiderocol's patent protection end?
Patent information for specific drugs can be complex and is subject to change. Information on the patent expiry for Cefiderocol can be found on resources like DrugPatentWatch.com [3].
What are the common side effects of Cefiderocol?
Common side effects reported in clinical trials for Cefiderocol include diarrhea, nausea, vomiting, infusion site reactions, headache, and dizziness [2].
Are there any alternatives to Cefiderocol for resistant infections?
Given the rise of antimicrobial resistance, treatment options for complicated infections caused by Gram-negative bacteria can be limited. Alternative treatment strategies may involve other classes of antibiotics, combinations of drugs, or therapies based on susceptibility testing results [2].
What is the regulatory status of Cefiderocol outside the US?
Cefiderocol has also received marketing authorization in other regions. For instance, it was approved by the European Medicines Agency (EMA) in 2020 [4].
What are the key challenges in developing antibiotics like Cefiderocol?
The development of new antibiotics is challenged by the rapid emergence of drug-resistant bacteria and the economic difficulties in bringing new antibiotics to market. Regulatory pathways and post-market surveillance play crucial roles in ensuring the continued availability and appropriate use of these essential medicines [4].
*
**Sources
1. U.S. Food & Drug Administration. (2019, December 20). FDA approves new antibiotic to treat complicated urinary tract infections. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-antibiotic-treat-complicated-urinary-tract-infections
2. Cefiderocol (Fetroja). (n.d.). Retrieved from https://www.drugpatentwatch.com/drug/cefiderocol
3. DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/
4. European Medicines Agency. (2020, April 24). Fetroja. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/fetroja